PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

McDonald, F; Mornex, F; Garassino, MC; Filippi, AR; Christoph, D; Haakensen, VD; Agbarya, A; Van den Heuvel, M; Vercauter, P; Chouaid, C; Pichon, E; Siva, S; Steinbusch, L; Peretz, I; Solomon, B; Decoster, L; Sawyer, W; Allen, A; Licour, M; Girard, N

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (4): S738